Cellectis S.A. (CLLS) vs Outlook Therapeutics (OTLK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Outlook Therapeutics (OTLK) has outperformed Cellectis S.A. (CLLS) over the past year, losing 55.2% versus a loss of 70.9%. Over five years, CLLS leads with a -88.5% price change compared with -98.7% for OTLK. Outlook Therapeutics is the larger company by market cap ($137.3 million vs $125.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | OTLK |
|---|---|---|
| Share price | $1.25 | $0.564 |
| Market cap | $125.90M | $137.30M |
| 1-day change | -6.72% | -4.41% |
| YTD return | -74.17% | -64.30% |
| 1-year return | -70.93% | -55.24% |
| 5-year return | -88.46% | -98.66% |
| EPS (TTM) | $-0.64 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $2.54 |
| 52-week low | $1.22 | $0.161 |
| Distance from 52-week high | -77.19% | -77.78% |
| Analyst consensus | none | none |
| Avg. price target upside | +326.40% | +791.84% |
| Average volume | 80.14K | 13.33M |
| Shares outstanding | 72.72M | 243.45M |
| Employees | 224 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OTLK has outperformed CLLS by 15.7 percentage points over the past year.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
CLLS vs OTLK FAQ
Which is bigger, Cellectis S.A. or Outlook Therapeutics?
Outlook Therapeutics (OTLK) is larger, with a market capitalization of $137.30M compared with $125.90M for Cellectis S.A. (CLLS).
Which stock has performed better over the past year, CLLS or OTLK?
OTLK returned -55.24% over the past 12 months, compared with -70.93% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Outlook Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Cellectis S.A. and Biotechnology: Biological Products (No Diagnostic Substances) for Outlook Therapeutics.